ArticleFrontiers in nutrition2026
Supplementation with 2'-fucosyllactose, a prebiotic human milk oligosaccharide (HMO), in a magnesium-containing medical food reduces chemotherapy-induced mucositis in Wistar rats.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucositis is a common debilitating complication of chemotherapy in cancer patients that limits enteral nutrition, causes diarrhea, dehydration and electrolyte wasting. 2'-fucosyllactose (2'-FL), a non-digestible oligosaccharide initially isolated from human milk, is critical in the development of gastrointestinal function and microbiome maturation in the newborn. Here, we demonstrate, that supplementation of 2'-FL in a medical food with magnesium (Humolyte®), protects Wistar rats from gastrointestinal mucosal injury from chemotherapeutic drugs doxorubicin, irinotecan, 5-flurouracil, and cisplatin. Supplementation with Humolyte® reduced weight loss and the severity of diarrhea from chemotherapy. Histopathology of ileal and colonic tissue showed preservation of overall mucosal anatomy including goblet cells and a markedly lesser inflammation. Humolyte® reduced hypertrophy and edema of oral mucosa caused by chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.